Streamlining Specialty Drug Prior Auth in Maryland for Enhanced RCM

Klivira empowers healthcare providers to navigate the complexities of specialty drug prior auth in Maryland, automating critical steps from benefit determination to multi-channel submission.

For revenue cycle directors and prior authorization coordinators in Maryland, managing specialty drug PAs presents unique challenges due to diverse payer policies and high-cost therapies. These workflows demand precision, often involving a split between medical and pharmacy benefits, and require meticulous documentation to prevent delays and denials. Klivira addresses these operational complexities, driving efficiency and improving time-to-therapy.

The Intricacies of Specialty Drug Prior Auth in Maryland

Maryland's healthcare landscape, encompassing state-specific Medicaid managed care plans and a varied commercial payer footprint, significantly shapes the specialty drug prior authorization process. Providers must contend with distinct policy libraries and submission channels for high-cost biologics, infused agents, and complex injectables. This environment necessitates robust systems to manage the nuanced requirements for both medical and pharmacy benefit drugs.

Key Operational Hurdles for Specialty Drug Prior Auth in Maryland

Accurately determining medical versus pharmacy benefit for varied specialty drugs across Maryland payers.
Navigating site-of-care policies for infused agents, which can vary significantly by payer and patient context.
Ensuring comprehensive step-therapy and prior-line therapy documentation to meet specific payer criteria.
Coordinating timely specialty pharmacy fulfillment post-approval, often with external partners.
Managing the complexities of manufacturer copay assistance programs, particularly concerning Medicare patients.

Klivira's Automated Approach to Maryland Specialty Drug PA

Klivira's platform is engineered to streamline specialty drug prior auth in Maryland by automating the most labor-intensive and error-prone steps. Our solution integrates directly with EMRs, leveraging advanced logic to interpret payer-specific requirements and route submissions through the correct channels, whether for medical or pharmacy benefits. This ensures a consistent, compliant, and efficient workflow tailored to the state's operational demands.

Klivira's Automated Workflow for Specialty Drugs in Maryland

Automated benefit-side determination, identifying medical vs. pharmacy benefit per drug, per payer, per patient context.
Multi-channel routing via NCPDP SCRIPT ePA for pharmacy benefits and X12 278 or Da Vinci PAS for medical benefits.
Automated capture of step-therapy and prior-line documentation from FHIR MedicationRequest and Observation resources.
Proactive identification of site-of-care policy requirements, surfacing mismatches before submission.
Coordinated post-approval handoff to specialty pharmacies for efficient fulfillment.

Leveraging Industry Standards for Maryland's PA Infrastructure

Klivira's platform adheres to critical industry standards to ensure seamless integration and interoperability within Maryland's diverse healthcare ecosystem. Our use of NCPDP SCRIPT for pharmacy ePA, FHIR for clinical data exchange, and X12 278 for medical benefit submissions ensures broad compatibility with EMRs and payer systems. This commitment to standards facilitates robust, evidence-grounded prior authorization processes.

Driving Efficiency and Reducing Delays for Maryland Providers

By automating the intricate process of specialty drug prior authorization, Klivira significantly reduces administrative burden and accelerates time-to-therapy for patients across Maryland. Our platform addresses critical failure modes such as benefit-side misclassification and documentation gaps, enabling clinics and hospitals to optimize their revenue cycle and enhance patient care for high-cost specialty medications.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefits for specialty drugs in Maryland?

Klivira's policy engine automatically determines whether a specialty drug falls under the medical or pharmacy benefit for a specific payer and patient in Maryland. This automated classification ensures the PA request is routed to the correct channel, preventing common delays due to misclassification.

Can Klivira integrate with our existing EMR system used in Maryland clinics or hospitals?

Yes, Klivira is designed for deep integration with EMR systems, including those widely used in Maryland. Leveraging standards like SMART on FHIR, we can extract necessary clinical documentation and patient history to populate PA requests efficiently, streamlining your existing workflows.

What standards does Klivira utilize for submitting specialty drug prior authorizations to Maryland payers?

Klivira employs industry-leading standards such as NCPDP SCRIPT for pharmacy benefit ePA, and X12 278 or Da Vinci PAS for medical benefit submissions. This multi-channel approach ensures compatibility with the diverse range of payer systems operating within Maryland.

How does Klivira address payer site-of-care policies for specialty infusions relevant to Maryland?

Klivira's platform incorporates site-of-care logic, aligning PA submissions with specific payer policies. If a Maryland payer's policy requires an alternative to a hospital outpatient department (HOPD) for a medical-benefit specialty drug, this information is surfaced proactively, helping avoid denials.

Does Klivira assist with the specialty pharmacy fulfillment process after a prior authorization is approved?

For pharmacy-benefit specialty drugs, Klivira coordinates the post-approval specialty pharmacy fulfillment workflow. While we don't manage the logistics of drug delivery, our system facilitates the handoff to the payer's specialty pharmacy partner, aiming to reduce overall time-to-medication for Maryland patients.